Global amyotrophic lateral sclerosis treatment market is projected to grow at a considerable CAGR of 5.5% during the forecast period (2020-2026). According to the National Institute of Neurological Disorder and Stroke (NINDS), sporadic amyotrophic lateral sclerosis is the most common form type contributed to 90% of cases in the US and Familial amyotrophic lateral sclerosis contributed 10%. The rising awareness related to amyotrophic lateral sclerosis treatment options, rising inclination towards the sedentary lifestyle, and increasing incidence and prevalence rate of amyotrophic lateral sclerosis disease are the major factors that are anticipated to drive the growth of the global market. 

Amyotrophic lateral sclerosis is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. The geriatric population is more prone to the development of amyotrophic lateral sclerosis disease. Therefore, the increasing geriatric population is fuelling the demand for amyotrophic lateral sclerosis treatment market across the globe. The permanent treatment option of this disease is not yet discovered however stem cell therapy and medication can be used to curtail the level of complication in patients suffering from the disease. The high cost associated with amyotrophic lateral sclerosis treatment and the availability of limited treatment options may restrain the growth of the amyotrophic lateral sclerosis treatment market across the globe.

Segmental Outlook  

The amyotrophic lateral sclerosis treatment market is segmented on the basis of treatment type. Based on the treatment type, the amyotrophic lateral sclerosis treatment market is segmented into medication, stem cell therapy, and others. Medication to showcase considerable growth based on treatment type. The growing FDA approval for the new drugs to treat amyotrophic lateral sclerosis disorders is anticipated to drive the growth of this market segment.  In addition, the easy and rapid access to a broad range of drugs and adequate products in the stock offered by pharmacies is a key factor contributing to the growth of the medication segment. Moreover, an increase in the e-commerce industry along with the preference of customers towards online pharmacy is anticipated to drive the growth of this market segment.

Global Amyotrophic Lateral Sclerosis Treatment Market Share by Treatment Type, 2019 (%)

Regional Outlook 

The global amyotrophic lateral sclerosis treatment market is further segmented on the basis of geography including North America, Europe, Asia-Pacific, and Rest of the World. North America is anticipated to hold a considerable market share during the forecast period. High prevalence of amyotrophic lateral sclerosis disorder due to the growing geriatric population is anticipated to be a key factor contributing to the high share of the market in the North America region. The presence of huge funding for R&D of the treatment drugs and therapies, proper medical reimbursement policies, and the rise in the awareness of this disease among people are some of the other factors that will make a considerable contribution towards the high share of market in the region. The availability of funding for the R&D of neurological disorders by major organizations such as The National Institute of Neurological Disorders and Stroke and National Institute of Health is anticipated to make a huge contribution towards the high share of the market in the region.

Global Amyotrophic Lateral Sclerosis Treatment Market Growth, by Region 2020-2026

Asia-Pacific to exhibit considerable growth during the forecast period 2020-2026

Rising patient pool suffering from amyotrophic lateral sclerosis disorder, improving healthcare infrastructure, growing R&D funding for new therapies, increasing per capita healthcare expenditure are anticipated to be the key factors driving the growth of the amyotrophic lateral sclerosis treatment market in the Asia-Pacific region. Furthermore, the growing geriatric population in the major economies of the region such as China, India, Japan, and South Korea which is susceptible to amyotrophic lateral sclerosis disorder is another key factor contributing towards the growth of the market in the Asia-Pacific region. However, low awareness related to the treatment options among the people of the low-income economies of the region is anticipated to hinder the growth of the market in the Asia-Pacific region.  

Market Players Outlook

The key players of amyotrophic lateral sclerosis treatment market include Mitsubishi Tanabe Pharma Corp., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., CORESTEM, Inc., BrainStorm Cell Ltd., Otsuka Pharmaceutical Co., Ltd., AB Science, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceutical Holding Company Ltd., and so on. These players are actively adopting different growth strategies such as new product launch, partnerships, collaboration, and mergers and acquisition among others to remain competitive in the market place. For instance, in January 2018, Sangamo Therapeutics, Inc. had entered into a collaboration with Pfizer Inc. to develop zinc finger protein transcription factors (ZFP-TFs), a gene therapy to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene. With this collaboration, the company aims to expand its therapeutics portfolio. 

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global amyotrophic lateral sclerosis treatment market. Based on the availability of data, information related to the products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.